Regeneron Pharmaceuticals, Inc.
807.65USD
-2.6600 (-0.33%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.2B | 13.1B | 14.2B | 14.3B | 16.9B | 18.4B |
| Q1 | 3.0B | 3.2B | 3.1B | 3.0B | 3.6B | — |
| Q2 | 2.9B | 3.2B | 3.5B | 3.7B | 4.3B | — |
| Q3 | 2.9B | 3.4B | 3.7B | 3.8B | 4.5B | — |
| Q4 | 3.4B* | 3.4B* | 3.8B* | 3.9B* | 4.6B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 38.22 | 34.77 | 38.34 | 41.48 | 53.55 | 50.38 |
| Q1 | 8.61 | 7.17 | 6.27 | 7.27 | 6.75 | — |
| Q2 | 7.47 | 8.50 | 12.41 | 12.81 | 12.23 | — |
| Q3 | 11.66 | 8.89 | 11.54 | 13.62 | 16.00 | — |
| Q4 | 10.55* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 10.20* |
| 7.97* |
| 7.78* |
| 15.61 |
| — |